# Increland

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/increland

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.cdincreland.com
- Latest round: Series A (Dec 26, 2025)
- Investors on record: 2

## About

Increland, based in Chengdu, China, focuses on the discovery and development of innovative pharmaceutical products, utilizing advanced technologies to enhance patient outcomes and address significant medical needs.Founded in 2020 in Chengdu, China, Increland specializes in pharmaceutical product discovery and development. The company has engaged in one notable deal, raising funding on December 26, 2025. The founder's prior history is not stated.Increland specializes in the discovery and development of innovative pharmaceutical products, leveraging advanced technologies such as crystal structure-based drug design, computer-aided drug design, protein degradation technologies, and peptide modification techniques. The company aims to create drugs that enhance patient outcomes for the pharmaceutical sector, targeting healthcare providers, hospitals, and research institutions in North America, Europe, and parts of Asia.Increland's revenue model is built on strategic partnerships and collaborations within the pharmaceutical industry, focusing on B2B transactions. Revenue is derived from contractual agreements and licensing arrangements based on the efficacy of their drug discoveries, with flagship products developed through proprietary research methodologies to meet specific therapeutic needs.In December 2025, Increland raised an undisclosed amount of Series A funding from new investors Star Capital and Dingfeng Asset Management. This funding will be utilized to advance new drug development in cancer immunotherapy and precision medicine. The company plans to expand its market presence, targeting new geographic regions in the pharmaceutical sector to enhance its portfolio by 2026.

## Funding rounds

- Series A, Dec 26, 2025 — Dingfeng Asset Management, Star Capital

## Investors

- Dingfeng Asset Management (https://capitalatlas.ai/funds/dingfeng-asset-management) — Series A
- Star Capital — Series A